Please select the option that best describes you:
Would you consider using an anthracycline-based regimen again for a breast cancer patient who previously received doxorubicin 10 years prior?
What are your thoughts with the new KEYNOTE-522 regimen? Would you just use carbo/paclitaxel/pembro part of the regimen or give as much doxorubicin as you can under 450 mg/m2 lifetime dose?
Answer from: Medical Oncologist at Academic Institution
I would not re-treat with an anthracycline for several reasons. She is at higher risk of heart failure (HF) by virtue of the prior exposure to anthracyclines, and you couldn't get in standard course of anthracyclines because of quickly exceeding the 450 mg/m2 limit where the risks HF increase drama...
Sign in or Register to read more